Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.41% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.94%, a 12.83% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.52%, a 4.87% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.31%, a 2.13% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.22%, a 72.95% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.52%, a 2.80% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.65%, a 5.87% decline from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.94%, a 16.78% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.23%, a 215.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.41% 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 3.94% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 4.52% 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 4.52% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 4.52% 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | 4.52% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 4.65% 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 4.65% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 4.65% 10-Q · filed 2025-07-28 | |||
| 2024-03-31 | 4.31% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.94% 10-K · filed 2025-02-27 | |||
| 2023-09-30 | 4.47% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 4.22% 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 4.22% 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | 4.23% 10-K · filed 2024-03-05 | |||
| 2022-09-30 | 4.11% 10-Q · filed 2023-10-30 | |||
| 2022-06-30 | 3.55% 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 2.44% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 1.34% 10-K · filed 2023-03-02 | |||
| 2021-09-30 | 1.17% 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 1.17% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 1.13% 10-Q · filed 2022-05-02 | |||
| 2020-12-31 | 1.67% 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 1.67% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 1.67% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 1.67% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 2.50% 10-K · filed 2021-03-04 | |||
| 2019-09-30 | 2.50% 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |